In the U.S., having sickle cell disease (SCD) continues to place a heavy clinical burden on patients, who often require multiple medications, frequent blood transfusions, and the use of opioids to control pain. Most individuals with SCD report high barriers to healthcare, with poor access to treatments and little effective pain management as major issues.
Meanwhile, though emerging treatments such as gene therapy are generating interest among doctors, these options are not yet widely used by patients, primarily due to barriers that include insurance denials.
These are among the findings of a new report, called the 2026 “Patient Chart Dynamix: Sickle Cell Disease (US),” from Spherix Global Insights, which reviewed 133 real-world patient charts collected from 86 doctors in the U.S. who specialize in blood diseases and cancer.
“As the therapeutic landscape evolves, the 2026 findings point to a pivotal transition period in sickle cell disease care — marked by rapid scientific progress, expanding therapeutic innovation, and rising physician optimism, yet constrained by operational and access barriers that must be resolved to translate breakthrough therapies into routine clinical practice,” Spherix stated in a company press release.
The company concluded that sickle cell care in the U.S. has reached what it called “an inflection point.”